Research And Development
Health
Manufacturing
ACADIA Pharmaceuticals
$25.999876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$25.99
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.62 (2.45%) Today
+$0.03 (0.12%) After Hours
Why Robinhood?
You can buy or sell ACAD and other stocks, options, ETFs, and crypto commission-free!
About
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. It operates through development and commercialization of innovative medicines segment. Read More The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Employees
430
Headquarters
San Diego, California
Founded
1993
Market Cap
3.65B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
2.26M
High Today
$26.10
Low Today
$25.45
Open Price
$25.45
Volume
370.08K
52 Week High
$28.67
52 Week Low
$12.77
Collections
Research And Development
Health
Manufacturing
Pharmaceutical
Technology
Medical
Biotechnology
News
Yahoo FinanceMay 9
Edited Transcript of ACAD earnings conference call or presentation 1-May-19 8:30pm GMT
Q1 2019 ACADIA Pharmaceuticals Inc Earnings Call SAN DIEGO May 9, 2019 (Thomson StreetEvents) -- Edited Transcript of ACADIA Pharmaceuticals Inc earnings conference call or presentation Wednesday, May 1, 2019 at 8:30:00pm GMT TEXT version of Transcript ================================================================================ Corporate Participants ================================================================================ * Elena H. Ridloff ACADIA Pharmaceuticals Inc. - Executive VP & CFO...
The Motley FoolMay 8
Why Acadia Pharmaceuticals Stock Slumped in April
What happened Acadia Pharmaceuticals (NASDAQ:ACAD), a mid-cap biopharma, saw its shares decline by 10.8% last month, according to data from S&P Global Market Intelligence. What provoked this double-digit sell-off? Acadia's shares fell victim to the politically charged drug-pricing debate in the United States. While biopharma stocks in general struggled in April because of this hot-button issue, Acadia's shares were hit particularly hard because the company has aggressively raised the price of its Parkinso...
Yahoo FinanceMay 7
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch Health Care Conference 2019
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2019 on Tuesday, May 14, 2019 at 10:40 a.m. Pacific Time in Las Vegas. A live webcast of ACADIA’s presentation will be accessible on the company’s website, www.acadia-pharm.com,...
Price Paid on Robinhood
10% Higher
Right Now
52 Week Low
$12.77
Average Price Paid
$23.65
52 Week High
$28.67
Earnings
-$0.62
-$0.56
-$0.50
-$0.44
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, After Hours